Abstract
Treatment response is heterogeneous. However the classical methods treat the treatment response as homogeneous and estimate the average treatment effects. The traditional methods are difficult to apply to precision oncology. The artificial intelligence (AI) is a powerful tool for precision oncology. It can accurately estimate the individualized treatment effects and learn optimal treatment choices. Therefore, the AI approach can substantially improve progress and treatment outcomes of patients. As one of AI approach, conditional generative adversarial nets for inference of individualized treatment effects (GANITE) have been developed. However, the GANITE can only deal with binary treatment and does not provide a tool for optimal treatment selection. To overcome these limitations, we modify conditional generative adversarial networks (MCGANs) to allow estimation of individualized effects of any types of treatments including binary, categorical and continuous treatments. We propose to use sparse techniques for selection of biomarkers that predict the best treatment for each patient. Simulations show that the CGANs outperform seven other state-of-the-art methods: linear regression (LR), Bayesian linear ridge regression (BLR), KNN, random forest classification (RF (C)), random forest regression (RF (R)), logistic regression (LogR) and support vector machine (SVM). To illustrate their applications, the proposed CGANs were applied to 256 patients with newly diagnosed acute myeloid leukemia (AML) who were treated with high dose ara-C (HDAC), Idarubicin (IDA) and both of these two treatments (HDAC+IDA) at M. D. Anderson Cancer Center. Our results showed that the MCGAN can more accurately and robustly estimate the individualized treatment effects than other state-of-the art methods. Several biomarkers such as GSK3, BILIRUBIN, SMAC are identified and a total of 30 biomarkers can explain 36.8% of treatment effect variation.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/18840713/
Funding Statement
Dr. Wei Lin is supported by the National Key R&D Program of China (Grant no. 2018YFC0116600), the National Natural Science Foundation of China (Grant no. 11925103), and by the STCSM (Grant no. 18DZ1201000).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is de-identified data. Exemption of IRB/oersight.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data with total of 256 newly diagnosed acute myeloid leukemia (AML) patients, treated with high dose ara-C (HDAC), Idarubicin (IDA) and HDAC+IDA were downloaded from M. D. Anderson Cancer Center.
http://bioinformatics.mdanderson.org/Supplements/Kornblau-AML-RPPA/aml-rppa.xls